In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EHRA Ivory (& above) Members, Fellows of the ESC and Young combined Members

Women as candidates for CRT: Are they less but better?

Session EHRA Essentials 4 You- ePublications

Speaker Ines Aguiar Ricardo

Event : EHRA Essentials 4 You 2020

  • Topic : arrhythmias and device therapy
  • Sub-topic : Cardiac Resynchronization Therapy
  • Session type : ePublication

Authors : I Aguiar-Ricardo (Lisbon,PT), A Nunes-Ferreira (Lisbon,PT), J Rigueira (Lisbon,PT), T Rdrigues (Lisbon,PT), N Cunha (Lisbon,PT), PS Antonio (Lisbon,PT), P Morais (Lisbon,PT), SC Pereira (Lisbon,PT), A Bernardes (Lisbon,PT), I Santos (Lisbon,PT), A Magalhaes (Lisbon,PT), H Neves (Lisbon,PT), FJ Pinto (Lisbon,PT), J De Sousa (Lisbon,PT), P Marques (Lisbon,PT)

I Aguiar-Ricardo1 , A Nunes-Ferreira1 , J Rigueira1 , T Rdrigues1 , N Cunha1 , PS Antonio1 , P Morais1 , SC Pereira1 , A Bernardes1 , I Santos1 , A Magalhaes1 , H Neves1 , FJ Pinto1 , J De Sousa1 , P Marques1 , 1Santa Maria University Hospital/CHULN, CAML, CCUL, Lisbon School of Medicine, Universidade de Lisboa, Cardiology - Lisbon - Portugal ,


Introduction: Women have been under-represented in trials of cardiac resynchronization therapy (CRT).  Most available data suggest that CRT has a greater clinical benefit in women than in men. However, further studies are needed to investigate the exact reasons for these results.

To compare the prognostic impact and response rate of CRT in women and man.

Methods: Prospective study, single-center study that included pts undergoing CRT implant from 2015 to 2019. Clinical and echocardiographic evaluation were made before CRT implant and between 6-12 months post-implant. Pts with EF elevations=10% or LV end-systolic volume (ESV) reductions=15% were classified as responders. Patients with EF elevations = 20% or ESV reductions=30% were classified as super-responders. All the parameters were compared between women and man. Prognostic impact of CRT was evaluated as total mortality by the Cox regression and Kaplan-Meier methods.

Results: From 2015-2019, 561 patients were submitted to CRT implant with a follow-up duration of 18.9±15.8 months. From these 148 (26.4%) were female (mean age 72.2±10 years, 22.4% ischemic, LVEF < 30% in 70.2%). The cardiovascular risk factors and comorbidities were similar in both populations (women and men). In the female group, dilated cardiomyopathy was more frequent than in men (71% vs 50.8%, p<0.01), with ischemic heart disease being the second most frequent etiology of heart failure.

The frequency of LBBB was similar in both groups (63.9% in women and 57.0% in men, p=NS) however the QRS duration was higher in women (164 ± 17 vs 160 ± 24, p=0.017). The baseline mean EF was similar (30.5±10.3ms in women and 30.3±11.4ms in men) but the ESV was lower (109.7±59.9 vs 138.4±64.6, p<0.001).

The prevalence of complications and need for surgical revision were similar in both groups.

The rate of CRT responders was similar in both groups, although tendentially higher in women (64.3% in women vs 55.2% in men, p=NS). On the other hand, super-responder rate was statistically significant (38% in women vs 25.1% in men, p=0.004). The long-term survival was similar in both groups.

Conclusion: The rate of super-responders was higher in women than in men. This may be explained by the higher prevalence of dilated cardiomyopathy in this subgroup of patients and by the fact that women have smaller hearts and a larger QRS duration at baseline, most likely to have a real LBBB. Long-term mortality of CRT was not gender related

The free consultation period for this content is over.

It is now only available year-round to EHRA Ivory (& above) Members, Fellows of the ESC and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are